Hipertensión arterial refractaria y la espironolactona. Análisis del ensayo clínico PATHWAY 2

摘要

A series of papers have been published in which a critical analysis is made about some of the most known evidences (clinical trials, records, Guides of clinical practice, etc) and of controversial issues of cardiovascular medicine in the last years. This time the results of the clinical trial, prevention and treatment of Hypertension with the therapy based in the algorithm PATHWAY 2 are appraised. This study showed that Spirinolactone is more effective as a fourth drug in the treatment of Refractory Arterial Hypertension, than Doxazosin and Bisoprolol, furthermore Spirinolcatone reduces half of the prevalence of this pathology. It is considered that in spite of its bias, this trial may have impact in the pharmacologic management of refractory hypertension.